drugset / Trial / NCT02451423
Neoadjuvant Atezolizumab in Localized Bladder Cancer
Phase 2
Completed
23 enrolled
Lawrence Fong
Bladder Cancer Advocacy Network · collabConquer Cancer Foundation · collabGenentech, Inc. · collabNational Cancer Institute (NCI) · collabThe V Foundation · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase II trial studies the best dose of atezolizumab in treating patients with bladder cancer that has not spread to other places in the body. Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Timeline
- Start
- 2016-03-29
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Publications
- Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 Jun 25;181(7):1612-1625.e13. doi: 10.1016/j.cell.2020.05.017. Epub 2020 Jun 3.
- Friebel E, Kapolou K, Unger S, Nunez NG, Utz S, Rushing EJ, Regli L, Weller M, Greter M, Tugues S, Neidert MC, Becher B. Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes. Cell. 2020 Jun 25;181(7):1626-1642.e20. doi: 10.1016/j.cell.2020.04.055. Epub 2020 May 28.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |